Related by context. All words. (Click for frequent words.) 74 statistically significant p = 71 statistical significance p = 71 statistically significant p 70 P ≤ 70 μmol L 70 % Confidence Interval 68 mg p = 68 mmHg p = 68 HbA 1c levels 68 % CI #.#-#.# [001] 68 baseline HbA1c 68 BMS p = 67 Xalatan R 67 Hazard Ratio HR 67 noninferiority 67 log# copies mL 67 PSA nadir 67 sensitivity specificity 67 pmol L 67 #.#mg/dL 66 creatinine ratio 66 mg kg Hematide 66 AUA Symptom Score 66 HOMA IR 66 XIENCE V PROMUS Stent 66 mL/min/#.# m 2 66 mmol l 66 DAS# CRP 66 g dl 66 μg L 66 mg BID dose 66 serum phosphate 66 HbA 1c 66 prospectively defined 66 HER2 expression 66 nmol liter 66 interquartile range 65 -#.# log# 65 morphometric vertebral fractures 65 x ULN 65 intact parathyroid hormone 65 % CI #.#-#.# [003] 65 placebo p = 65 BENICAR HCT 65 pg mL 65 HbA1C levels 65 CI -#.# 65 serum urate 65 serum HBV DNA 65 Stent p = 65 lumbar spine BMD 65 r2 = 65 A1c levels 65 achieved statistical significance 65 postintervention 65 glycosylated hemoglobin HbA1c 65 hemoglobin A1c HbA1c 65 HbA 1C 65 alanine aminotransferase ALT 65 viral kinetics 65 IOP lowering 64 MMSE score 64 serum estradiol 64 Ryan Schnitz Buell 64 complete cytogenetic response 64 dose proportionality 64 atorvastatin #mg 64 Kaplan Meier analysis 64 TAXUS p value 64 definite stent thrombosis 64 ng dL 64 serum phosphorus 64 log# IU mL 64 pCR 64 Angelle Savoie Suzuki 64 placebo p 64 confidence intervals CIs 64 undetectable HBV DNA 64 mIU ml 64 confidence interval #.#-#.# 64 leukocyte count 64 achieved ACR# 64 mcg mL 64 nondiabetic patients 64 Greg Stanfield GXP 64 #.#ng/ml 64 mean baseline HbA1c 64 pg ml 64 genotypic resistance 64 DAS# remission 64 -#.# log# copies mL 64 Bonferroni correction 64 HIV RNA 64 relapsed MM 64 MIC# [001] 64 microg 64 serum urate levels 64 PCT VALUE DATE 64 p ≤ 64 diastolic blood pressures 64 NNT = 64 glycated hemoglobin levels 64 thyroglobulin 64 intraobserver 64 sUA 64 CR nPR 64 PREZISTA r arm 64 serum aminotransferase levels 64 attain statistical significance 64 baseline serum creatinine 64 HBeAg seroconversion 64 ug ml 64 plasma pharmacokinetics 64 regression coefficients 64 virological response 64 p = .# [002] 64 multivariate Cox 64 homocysteine concentrations 64 CC genotype 64 corrected QT interval 63 μg mL 63 titrated glipizide 63 Pharmacokinetic parameters 63 mITT population 63 BPH Symptom Score 63 Non inferiority 63 ARCOXIA 63 Cruz Pedregon Solara 63 HBV DNA levels 63 ARB telmisartan 63 hsCRP levels 63 multivariable analysis 63 abacavir lamivudine 63 #.#/#.# mmHg [001] 63 odds ratios ORs 63 ug mL 63 mEq L 63 #mg dose [002] 63 interobserver reliability 63 p = #.# [003] 63 mean baseline A1C 63 calculated creatinine clearance 63 urine albumin 63 echocardiographic parameters 63 -#.# ± [002] 63 postmenopausal osteoporotic women 63 ug kg 63 serum phosphorous 63 locoregional recurrence 63 serum concentrations 63 umol L 63 histologic subtype 63 PASI scores 63 per deciliter mg 63 Melanie Troxel Charger 63 CIMZIA ™ 63 Ron Krisher Cavalier 63 tHcy 63 CCyR 63 creatinine clearance 63 NPH insulin 63 aspartate aminotransferase AST 63 Pyratine XR TM 63 mmol kg 63 Hb A1C 63 oxycodone CR 63 MAGE A3 ASCI 63 QTcF 63 MADRS score 63 fin div 63 gadobutrol 63 biochemical relapse 63 Chris Rivas Buell 63 specific antigen PSA 63 microbiologically evaluable 63 Primary endpoints 63 aminotransferases 63 lispro 63 sustained virological response 63 posaconazole 63 ALT elevation 63 baseline LDH 63 μg dL 62 K ras mutations 62 Tony Pedregon Impala 62 MDRD equation 62 mU liter 62 clinically meaningful improvement 62 virologic failure 62 cTnI 62 antibody titer 62 dosing cohort 62 serum calcium 62 conjugated equine estrogens 62 serum lipid 62 Supplementary Table 62 univariate analysis 62 advanced adenoma 62 estimated GFR 62 haematologic 62 colorectal adenoma 62 elevated ALT 62 angiographic restenosis 62 Cronbach alpha 62 HbA1C 62 % CI #.#-#.# [004] 62 apolipoprotein B 62 μg kg 62 Doxil ® 62 mmol L 62 aspartate aminotransferase 62 Gary Densham Monte Carlo 62 SUVmax 62 TLUS 62 #mg/day [002] 62 intraclass correlation coefficient 62 p = NS 62 seropositivity 62 SVR# 62 intravesical therapy 62 MBq 62 oral allopurinol 62 iPTH 62 TRAIL R1 62 tipranavir r 62 troponin T 62 lopinavir r arm 62 rho = 62 #mg/dL [002] 62 CrCl 62 #ng/ml 62 mCi 62 univariate 62 glomerular filtration rate 62 hemoglobin Hb 62 seroprotection 62 #mg/dL [001] 62 Del Worsham Solara 62 binary restenosis 62 statin monotherapy 62 Serum creatinine 62 Tony Bartone Monte Carlo 62 dose cohort 62 secondary efficacy endpoint 62 linaclotide treated 62 STRIDE PD 62 candesartan cilexetil 62 multivariable adjusted 62 favorable pharmacokinetic profile 62 glycated hemoglobin 62 interobserver agreement 62 certolizumab 62 mg/m2 dose 62 Ron Capps Charger 62 Kenny Koretsky Stratus 62 log# reduction 62 sUA levels 62 hyperphenylalaninemia HPA due 62 Cruz Pedregon Monte Carlo 62 mg kg dose 62 serum PTH 62 EDSS score 62 ertapenem 62 methotrexate monotherapy 62 anemia hemoglobin 62 mcg albinterferon alfa 2b 62 lactate dehydrogenase 62 -#.# mg dL [002] 62 nonfatal MI 62 ß = 62 Ishak fibrosis score 62 preoperative PSA 62 nmol L 62 Jeff Arend Impala 62 Kenny Koretsky Cobalt 62 KRAS mutations occur 62 Secondary efficacy endpoints 62 AST ALT 62 Postoperative complications 62 conditional logistic regression 62 EpCAM expression 61 ruboxistaurin 61 alanine aminotransferase 61 serum uric acid 61 HBeAg negative patients 61 HbA1c levels 61 low dose Iluvien 61 HBeAg 61 TREO + Y#O# 61 urinary N telopeptide 61 oral FTY# 61 eplerenone 61 HGPIN 61 Gary Scelzi Charger 61 annualized relapse 61 ATACAND 61 glycated hemoglobin HbA1c 61 serum TSH 61 RE LY ® 61 Phil Burkart Monte Carlo 61 MERLIN TIMI 61 #mg BID [001] 61 mmHg diastolic 61 budesonide pMDI 61 fluticasone salmeterol 61 -#.# USD JPY [002] 61 Gary Scelzi Dodge Stratus 61 μg g 61 null hypothesis 61 Whit Bazemore Dodge Stratus 61 octreotide LAR 61 Cmax 61 NHANES III 61 CIN2 + 61 insulin detemir 61 comparator arm 61 Bulk density 61 concomitant medications 61 -#.# ± [001] 61 pmol liter 61 SGPT 61 nmol l 61 mL/min/#.# m2 61 g cm 61 PCWP 61 periprocedural 61 uM 61 Hazard Ratio = 61 Tony Pedregon Monte Carlo 61 spirometric 61 response CCyR 61 univariate analyzes 61 Max Naylor Stratus 61 Hb A1c 61 #ppb gold 61 lowest tertile 61 Solid Tumors criteria 61 nanograms milliliter 61 ADCS CGIC 61 TIMP 1 61 Haptoglobin 61 kappa = 61 log# 61 baseline A1C 61 QT QTc 61 LDL HDL 61 prespecified secondary 61 intravenous dosing 61 virologic response 61 ACR# response 61 eosinophil count 61 posttreatment 61 evaluable subjects 61 coronary stenosis 61 Jeg Coughlin Cobalt 61 Ag g tx 61 tapentadol ER 61 ± #.#mm [001] 61 serum leptin 61 nmol 61 Contrave# 61 unfractionated heparin UFH 61 bivalirudin monotherapy 61 serum potassium 61 Operative mortality 61 Solid Tumors RECIST 61 mmol L. 61 thyrotropin levels 61 Pearson correlation coefficient 61 trastuzumab Herceptin ® 61 prospectively stratified 61 Angelle Sampey Suzuki 61 Gann angle 61 Eddie Krawiec Harley Davidson 61 serum testosterone 61 endometrial thickness 61 chlorambucil 61 invasive carcinomas 61 ULORIC 61 Xalatan ® 61 Del Worsham Monte Carlo 61 steroid dexamethasone 61 nonfasting triglyceride levels 61 LV ejection fraction 61 glulisine 61 Gary Scelzi Dodge Charger 61 μg liter 61 OGTT 61 clinico pathological 61 reduce serum phosphate 61 dose Iluvien 61 timepoint 61 plasma leptin 61 Multivariate analysis 61 -#.# p = 60 oral diclofenac 60 Ron Krisher Cobalt 60 Robert Hight Mustang 60 latanoprost 60 hemoglobin A1c levels 60 conjugated estrogens 60 efavirenz EFV 60 #.# Swiss francs 60 neutrophil counts 60 preintervention 60 Gary Densham Chevy Impala 60 fasting triglycerides 60 NIHSS score 60 intima media thickness 60 sustained virologic response 60 CANCIDAS 60 serum creatinine levels 60 pT3 60 periprocedural MI 60 X ULN 60 #.#g t Ag [005] 60 mITT 60 corticosteroid dose 60 Geno Scali Suzuki 60 oral Hycamtin 60 pharmacokinetic equivalence 60 arterial thromboembolic events 60 Eric Medlen Mustang 60 chi squared 60 parous women 60 CIMZIA TM 60 noninferior 60 4mg/kg 60 #.# US#YT = 60 biologic DMARD 60 pegylated interferon alfa 60 ng dl 60 Whit Bazemore Stratus 60 PCA3 scores 60 Greg Stanfield GTO 60 tirofiban 60 urate lowering therapy 60 EDEMA3 trial 60 mcg dL 60 elevated IOP 60 Shawn Gann Suzuki 60 highly emetogenic 60 underwent surgical resection 60 advanced adenomas 60 Jeg Coughlin Cavalier 60 mg d 60 troponins 60 Crohn Disease Activity 60 platelet reactivity 60 IU mL 60 Pharmacokinetic 60 albumin excretion 60 virological failure 60 mg Proellex 60 correlation coefficients 60 microbiological eradication 60 CDAI score 60 mesalamine granules 60 FDG uptake 60 tolterodine ER 60 tacrolimus ointment 60 serum ALT 60 CTAP# Capsules 60 serum magnesium 60 ejection fractions 60 ppm Au 60 #OHD 60 QIDS SR 60 Erica Enders Cobalt 60 LE Tonglet Suzuki 60 Vancocin p = 60 systemic embolism 60 % CI #.#-#.# [005] 60 mg dL 60 HCV replicon 60 UGT#A# * 60 Antron Brown Suzuki 60 unfractionated heparin 60 Rating Scale BPRS 60 mg eq 60 CVD mortality 60 β blockers 60 g dL 60 cEVR 60 serum retinol 60 plasma HCV RNA 60 % CI #.#-#.# [008] 60 Platelet counts 60 pharmacodynamic properties 60 lipid parameters 60 IU ml 60 QTc 60 Cu Eq 60 efficacy endpoint 60 R# #mg BID 60 eGFR 60 #mg doses [002] 60 T2 lesions 60 highest tertile 60 confidence interval CI 60 avosentan 60 Eur J Endocrinol 60 R0 resection 60 atazanavir ritonavir 60 maximally tolerated dose 60 caspofungin 60 biochemical recurrence 60 mmol 60 Cruz Pedregon Impala 60 mIU L 60 aminotransferase levels 60 dose clopidogrel 60 peak plasma concentrations 60 NATRECOR ® 60 moderate renal impairment 60 symptomatic intracranial hemorrhage 60 ng mL 60 APTIVUS r 60 Ceplene/IL-2 60 fasting plasma glucose FPG 60 lactate dehydrogenase LDH 60 Matt Guidera Buell 60 Index CDAI 60 P = .# 60 adenoma recurrence 60 #.#g/day 60 mcg BID 60 PRADAXA #mg 60 Del Worsham Impala 60 myocardial viability 60 TT genotype 60 hypogonadal 60 #.#mmol L [001] 60 neuropathy sensory 60 fluvastatin 60 Recurrence Score 60 elevated LDH 60 response pCR 60 tPSA 60 infliximab monotherapy 60 IFN α 60 ritonavir boosted 60 cardiac troponin T 60 invasive aspergillosis 60 lopinavir r 60 serum IGF 60 mmHg p 60 efficacy evaluable 60 lymphocyte count 60 IIIa inhibitor 60 carotid IMT 60 ezetimibe simvastatin 60 lanthanum carbonate 60 hepatorenal syndrome 60 β blocker 60 elevated creatinine 60 IV bisphosphonates 60 V. Gaines Stratus 59 mcg QD 59 albumin excretion rate 59 myocardial necrosis 59 urinary albumin 59 ARCALYST ® 59 Steve Spiess Cobalt 59 serum lipid levels 59 carotid stenosis 59 ASCUS 59 ALT flares 59 carcinoembryonic antigen 59 multivariate analyzes 59 pharmacodynamic parameters 59 invasive lobular 59 AUC0 59 oxcarbazepine 59 SCIg 59 dapagliflozin plus 59 #ug [002] 59 Mg Uk 59 Baseline characteristics 59 transaminase elevations 59 #.#-#.# [011] 59 hemoglobin concentrations 59 apremilast 59 biopsy Gleason 59 urine cytology 59 eNO 59 % tretinoin Gel 59 timolol 59 NIHSS 59 low dose cytarabine 59 5-fluorouracil/leucovorin 59 dopamine partial agonist 59 logistic regression models 59 reinfarction 59 CI #.#-#.# [002] 59 Lantus ® 59 mm ³ 59 atherogenic dyslipidemia 59 DOXIL 59 HbA1c 59 NOAEL 59 serum homocysteine 59 PSADT 59 recurrent venous thromboembolism 59 ACR# responses 59 logistic regression analysis 59 μg dose 59 FOLFOX4 59 DLTs 59 Gary Densham Impala 59 FOLFOX6 59 rFSH 59 erythrocyte sedimentation rate 59 Erica Enders Stratus 59 hepatic enzymes 59 peak VO2 59 PITX2 methylation 59 nicardipine 59 #.#mmol L [002] 59 baseline Hb 59 parasitaemia 59 ABCB1 59 pretest probability 59 pharmacokinetic PK profile 59 mutated K ras 59 neutrophil count 59 mg TID 59 intraclass correlation coefficients 59 NNRTI resistance 59 active comparator 59 intracranial hemorrhage ICH 59 AGHD 59 Engerix B 59 serum HCV RNA 59 serum CRP 59 Pharmacodynamic 59 protein excretion 59 infusional 5-FU/LV 59 8 OHdG 59 Craig Treble Suzuki 59 HBeAg negative 59 μg d 59 unrounded 59 nanomolar 59 mm Hg diastolic 59 mg tid 59 nonnucleoside reverse transcriptase inhibitors 59 liposomal amphotericin B 59 irbesartan 59 ibandronate 59 familial aggregation 59 serum phosphate levels 59 rapid virologic response 59 apnea hypopnea index 59 tolvaptan 59 postoperative mortality 59 bovine thrombin 59 Mg Usa 59 hepatic enzyme 59 chemoradiation therapy 59 #Gy 59 treat NNT 59 Interrater reliability 59 prolonged QT interval 59 secondary efficacy endpoints 59 recurrent VTE 59 microalbumin test 59 velafermin 59 Viral load 59 Lp PLA 2 59 mU L 59 serum sodium concentration 59 QTc prolongation 59 baseline FEV 59 aldosterone antagonist 59 MoxDuo TM IR 59 NYHA functional class 59 asymptomatic carotid stenosis 59 Cystatin C 59 intramuscular dose 59 rosuvastatin #mg 59 hemodynamically significant 59 antiretroviral naïve 59 desvenlafaxine succinate 59 lipid lowering agents 59 hydroxyvitamin D levels 59 mCi kg 59 hemoglobin A1C 59 atheroma volume 59 adjunctive placebo 59 ACR# ACR# 59 MDRD 59 #ppb Au [002] 59 interferon alfa 2b 59 anthracycline containing 59 NAbs 59 Yuan Keywords MARKETS 59 dosage regimens 59 mcg ml 59 NATRECOR R 59 CR CRu 59 maximal doses 59 postoperative complication 59 cytoreductive nephrectomy 59 macroalbuminuria 59 enoximone 59 severe neutropenia 59 virologic responses 59 confirmed CCyR 59 clinicopathological features 59 prednisone prednisolone plus 59 median PFS 59 total thyroidectomy 59 remission CR 59 logistic regression model 59 Shawn Gann Buell 59 pT2 59 composite endpoint 59 metformin hydrochloride 59 dalteparin 59 #mg #mg #mg [003] 59 Eric Medlen Ford Mustang 59 oral rivaroxaban 59 ximelagatran 59 folate vitamin B6 59 pharmacodynamic PD 59 Scott Kalitta Solara 59 EURIDIS 59 prespecified 59 ExTRACT TIMI 59 symptomatic VTE 59 pulmonary exacerbations 59 hematopoietic cancers 59 HES CEL 59 CTEPH 59 elotuzumab 59 5-FU/LV 59 Gary Scelzi Stratus 59 PREZISTA r 59 plus prednisone prednisolone 59 elevated LDL cholesterol 59 Tarceva TM 59 rALLy trial 59 ALA PDT 59 plasma homocysteine 59 TNSS 59 fructosamine 59 eU#O# 59 everolimus eluting stents 59 cTnT levels 59 Kaplan Meier 59 FOLPI 59 primary efficacy endpoints 59 plasma cortisol 59 cTnT 59 grade cervical intraepithelial 59 Response Evaluation Criteria 59 exhaled NO 59 colesevelam HCl 59 idraparinux 59 obstructive coronary artery 59 tumor histology 59 gemcitabine carboplatin 58 REYATAZ r arm 58 serum vitamin D 58 F FDG PET 58 clodronate 58 delafloxacin 58 sitosterol 58 hemagglutination inhibition 58 dosing cohorts 58 paclitaxel eluting stents 58 fosamprenavir 58 estimated glomerular filtration 58 serum calcium levels 58 serum ferritin 58 contrast induced nephropathy 58 % CI #.#-#.# [007] 58 T2 lesion volume 58 galiximab 58 m@#.# g t Au [003] 58 pharmacologically active isomer 58 crizotinib PF # 58 CK MB 58 TEAEs 58 NEVO ™ 58 interobserver 58 nmol L. 58 cilostazol 58 oral hypoglycemic agents 58 Hycamtin ® 58 tobramycin inhalation solution 58 amoxicillin clavulanate 58 t/m3 58 deciliter 58 #mg/dl 58 arterial thickening 58 saline placebo 58 hypogonadal men 58 flutamide 58 mg XP# 58 advanced neoplasia 58 serum biomarkers 58 HBV infections 58 tranylcypromine 58 radezolid 58 regression coefficient 58 K DOQI 58 FluCAM 58 normal ULN 58 serum PSA 58 HPV-#/# 58 Strategy Attempt longs 58 serum cortisol 58 mg QD 58 chest radiographs 58 serum LDL cholesterol 58 balsalazide 58 HER2 positivity 58 elevated transaminases 58 isoprostane 58 pharmacokinetic characteristics 58 Pegasys plus Copegus 58 mild renal impairment 58 adnexal mass 58 ara C 58 Lupuzor ™ 58 REMINYL ® 58 HCV antibody 58 mg ustekinumab 58 Kaplan Meier curve 58 BENICAR 58 Gary Densham Mustang 58 CRESTOR #mg 58 DAS# [002] 58 3mg/kg 58 THD + N 58 angiographic outcomes 58 rs# [004] 58 μmol l 58 locoregional 58 pyrexia mucositis sepsis febrile 58 tenofovir emtricitabine 58 hematological parameters 58 somatostatin analog 58 nodular partial response 58 cobiprostone 58 m@#.# g t [004] 58 postprocedure 58 AXIRON ™ 58 mg qd 58 prucalopride 58 LEXIVA r 58 Bonferroni 58 SSRI SNRI 58 statistical significance 58 χ 58 AEGR 58 PEG IFN 58 MCyR 58 tertile 58 XIENCE V vs. 58 FDA defined valvulopathy 58 bronchoalveolar lavage 58 carotid intima media 58 Sensitivity analyzes 58 PSA kinetics 58 mCRC patients 58 #F FDG PET 58 liver histology 58 transferrin saturation 58 Sustained virologic response 58 amprenavir 58 debulking surgery 58 urodynamic 58 sham injections 58 AUCs 58 peginterferon alfa 2a 58 oxycodone IR 58 serum clusterin levels 58 florbetaben 58 carotid artery thickness 58 Virulizin ® 58 salmeterol fluticasone propionate 58 oral antidiabetic medication 58 evaluating tivozanib 58 #.#g Au t [003] 58 seroconverted 58 B7 H3 58 oncologic outcomes 58 - -Schwenkler 58 CIMZIA TM certolizumab pegol 58 ETDRS 58 N telopeptide 58 picogram 58 imipenem 58 nonvertebral fracture 58 rizatriptan 58 pegaptanib 58 XIENCE V demonstrated 58 tumor xenograft models 58 femtogram 58 RECIST Response Evaluation Criteria 58 Hector Arana Buell 58 microgram kg 58 thickness CIMT 58 nonischemic 58 hip BMD 58 histopathologic findings 58 sorafenib tablets 58 fraction LVEF 58 Hazard Ratio 58 salmeterol fluticasone 58 Xanafide 58 anti HBs 58 heterozygotes 58 paricalcitol 58 metabolite concentrations 58 MACCE 58 mcg dose 58 etiologic 58 HIV uninfected 58 thyrotropin 58 adefovir treated 58 microdose 58 μg ml 58 #ppb [003] 58 mcg kg 58 Fasting glucose 58 azilsartan medoxomil 58 6MWD 58 Visual acuity 58 plus dexamethasone 58 cells uL 58 femoral neck BMD 58 tipranavir 58 analgesic efficacy 58 IgG antibody 58 LT NS# 58 kΩ 58 allele frequencies 58 PROCTOCORT ® Suppository Hydrocortisone 58 d dimer 58 H. pylori eradication 58 gm t 58 Bezielle 58 tertiles 58 MGd 58 serum prostate 58 #ppb [001] 58 virologic 58 nadolol 58 resected pancreatic cancer 58 mg q#h 58 serum antibody 58 pretreatment serum 58 histological subtype 58 PLX STROKE targeting 58 renal cell carcinomas 58 histologically confirmed 58 gm dl 58 Folfox 58 LUMIGAN ® 58 Brief Psychiatric 58 telaprevir dosed 58 INCB# [003] 58 ratio ICER 58 #mmHg [002] 58 permanently discontinue Vectibix 58 unresectable tumors 58 hematologic toxicity 58 #-#,# mg 58 RRM1 58 PREZISTA ritonavir 58 ^ sup -1 58 ANOVA 58 symptomatic intracerebral hemorrhage 58 liver transaminases 58 brivaracetam 58 inhibin B 58 revascularizations 58 multiple logistic regression 58 hypophosphatemia 58 leukopenia 58 HDRS 58 budesonide foam 58 LH FSH 58 transaminases 58 adriamycin 58 LPV r 58 % CI #.#-#.# [006] 58 mg dose 58 kilogram mg kg 58 mIU mL 58 curative resection 58 salmeterol HFA MDI 58 CsA 58 VELCADE melphalan 58 gemcitabine cisplatin